UBS Asset Management Americas Inc. cut its holdings in BIO-TECHNE Corp (NASDAQ:TECH) by 5.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 30,807 shares of the biotechnology company’s stock after selling 1,657 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in BIO-TECHNE were worth $3,991,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Advisory Services Network LLC grew its position in shares of BIO-TECHNE by 1,423.3% in the 4th quarter. Advisory Services Network LLC now owns 1,112 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 1,039 shares during the period. Zions Bancorporation bought a new stake in BIO-TECHNE in the 3rd quarter valued at approximately $178,000. Gofen & Glossberg LLC IL bought a new stake in BIO-TECHNE in the 4th quarter valued at approximately $205,000. Aull & Monroe Investment Management Corp bought a new stake in BIO-TECHNE in the 4th quarter valued at approximately $214,000. Finally, Turner Investments LLC bought a new stake in BIO-TECHNE in the 3rd quarter valued at approximately $242,000. Institutional investors and hedge funds own 97.15% of the company’s stock.
In other news, Director Charles A. Dinarello sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $136.06, for a total transaction of $680,300.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 3.40% of the company’s stock.
Shares of BIO-TECHNE Corp (NASDAQ:TECH) opened at $146.56 on Wednesday. BIO-TECHNE Corp has a 12 month low of $98.22 and a 12 month high of $148.26. The stock has a market capitalization of $5,490.00, a P/E ratio of 66.62, a PEG ratio of 2.81 and a beta of 0.75. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.49 and a current ratio of 3.10.
BIO-TECHNE (NASDAQ:TECH) last announced its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.10. BIO-TECHNE had a return on equity of 14.39% and a net margin of 19.17%. The company had revenue of $154.15 million for the quarter, compared to analysts’ expectations of $145.93 million. During the same quarter in the prior year, the business posted $0.81 EPS. The business’s revenue was up 16.9% compared to the same quarter last year. research analysts forecast that BIO-TECHNE Corp will post 4.01 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 2nd. Stockholders of record on Friday, February 16th were paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date was Thursday, February 15th. BIO-TECHNE’s dividend payout ratio is currently 58.18%.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/03/14/bio-techne-corp-tech-shares-sold-by-ubs-asset-management-americas-inc.html.
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BIO-TECHNE Corp (NASDAQ:TECH).
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.